

OMICS GROUP



OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over **400** leading-edge peer reviewed Open Access Journals and organizes over **300** International Conferences annually all over the world. OMICS Publishing Group journals have over **3 million** readers and the fame and success of the same can be attributed to the strong editorial board which contains over **30000** eminent personalities that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than **1000** International Societies to make healthcare information Open Access.

OMICS Journals are welcoming Submissions

OMICS Group welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS Group follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website:

<http://omicsonline.org/Submitmanuscript.php>

Mohammad S Shawaqfeh

Editor PPT

- Mohammad S Shawaqfeh is an Assistant Professor at the Department of Pharmacy Practice for the College of Pharmacy at NOVA Southeastern University. Currently, Dr. Shawaqfeh is also has a practice site at Palm Beach Gardens Medical Center for Advanced internal Medicine. Dr. Shawaqfeh has been a long-time pharmacist since 1993 and practiced pharmacy in Jordan, Saudia Arabia, Bahrain and United States. Dr. Shawaqfeh also holds memberships in numerous professional associations such as the AphA, ACCP, ASHP, AAPS, Jordan Pharmacist Association and Sigma Xi. Dr. Shawaqfeh received numerous scholarships to continue his education in pharmaceutical sciences. While studying, the research was an imminent part of Dr. Shawaqfeh's career. The research areas focused on pharmacokinetics, drug metabolism, clinical pharmacy, pharmacogenomic, and transplantation. In addition, Dr. Shawaqfeh has a clinical pharmacist experience at world class renowned University of Pittsburgh Medical Center at drug Use and disease state management. Born in Jordan, Dr. Shawaqfeh received his Bachelor of Science (1993) and diplome (2000) degrees in pharmacy from the Jordan University of Science and Technology in Jordan. He was awarded his Master of Science in pharmacy (2006) and Pharm.D.(2007) degrees from University of Iowa. He also, earned his Clinical Science research Certificate (2011) from school of Medicine at University of Pittsburgh, PA, and recently awarded his PhD in Clinical Pharmaceutical sciences (2014) from University of Pittsburgh, School of Pharmacy. Dr. Shawaqfeh is starting his career at Nova Southeastern University with a balanced split between clinical services at practice site, teaching , research and community service. He is currently licensed to practice pharmacy in PA and FL and holds a consultant pharmacy License in FL.

Biography

- The primary goal of our research has been to identify factors that regulate the pharmacokinetics and pharmacodynamics of drugs in different patient populations in order to optimize drug therapy . We are interested in investigating the process of absorption, distribution, transport (p-glycoprotein and other transporters), metabolism (phase 1 and phase 2 pathways) and excretion of drugs in patients. My interest is in clinical pharmacokinetics and biopharmaceutics of drugs in different patient populations that include metabolism and drug-drug interactions. Pharmacogenetic testing is an area of interest as a tool to optimize therapies. An initiative towards Informatics research with an evaluation of CPOE trends and benefits is a growing area of interest as well.

Research Interests

- 2014 Vitamin B6 deficiency following transplantation, podia presentation in HPD Research Day, Nova Southeastern University, Davie, FL
- 2011 Mechanistic analysis of Vitamin B6 deficiency following small bowel Transplantation, Podia Presentation in ISBTS, International Small Bowel Transplantation Symposium, Washington D.C.
- 2010 Clinically Relevant Drug Interactions Mediated By Drug Transporters, Pharmacy Grand Rounds, ACPE Accredited, Sponsored by University of Pittsburgh Center for Continuing Education in the Health Sciences.
- 2010 Therapeutic Approaches to Acute Insomnia in Hospitalized Patients, University of Pittsburgh Medical Center, Drug Use and Disease State Management Program.
- 2009 Expression and activity of drug metabolizing enzymes and transporters during acute rejection of transplanted non-metabolic organ (Limb Transplantation)
- 2008 Acute rejection of the intestinal graft alters Oral absorption/Bioavailability of drugs in Small Bowel Transplant Patients.
- 2008 Liquid chromatography–mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly (ADP-ribose) polymerase.

ORAL PRESENTATIONS

Pharmacokinetics, sometimes described as what the body does to a drug, refers to the movement of drug into, through, and out of the body.—the time course of its absorption

Pharmacokinetics

PHARMACOKINETICS

“What the body does to the drug”

Pharmacokinetics (PK)

- ★ The study of the **disposition** of a drug
 - ★ The disposition of a drug includes the processes of **ADME**
 - **Absorption**
 - **Distribution**
 - **Metabolism**
 - **Excretion**
 - **Toxicity**
- } **Elimination**

ABSORPTION

BLOOD STREAM

Protein bound

DISTRIBUTION

Tissue bound

ELIMINATION

METABOLISM

Metabolites

DISCOVERY PHASE




DEVELOPMENT PHASE



Drug discovery and development

- 10-15 years to develop a new medicine
- Likelihood of success: 10%
- Cost \$800 million - 1 billion

DRUG R&D



- Pharmacokinetics
- Animal Toxicity
- Miscellaneous
- Adverse Effects in Man
- Commercial Reasons
- Lack of Efficacy

Patients may suffer:

- **Toxic drugs may accumulate**
- **Useful drugs may have no benefit because doses are too small to establish therapy**
- **A drug can be rapidly metabolized.**

Importance of PK studies

Routes Of Administration

Routes Of Drug Administration

Parenteral

Enteral

Injection

Topical

Respiratory

Rectal

Oral

OMICS Group Open Access Membership

OMICS publishing Group Open Access Membership enables academic and research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors.

For more details and benefits, click on the link below:

<http://omicsonline.org/membership.php>



Approved By

Editorial Board member:

Mohammad S Shawaqfeh

E-signature: Mohammad S Shawaqfeh